M Zaffaroni
Overview
Explore the profile of M Zaffaroni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
706
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Masciulli C, Portaccio E, Goretti B, Niccolai C, Simone M, Viterbo R, et al.
Neurol Sci
. 2024 Nov;
46(2):1013-1017.
PMID: 39581901
Objective: Cognitive impairment affects approximately 30% of pediatric onset Multiple Sclerosis (POMS) patients with a negative impact on everyday life. The aim of this study was to evaluate the feasibility...
2.
Mazzola G, Bergamaschi L, Pedone C, Vincini M, Pepa M, Zaffaroni M, et al.
Clin Transl Radiat Oncol
. 2023 Sep;
43:100670.
PMID: 37736140
Aims: The number of Proton Therapy (PT) facilities is still limited worldwide, and the access to treatment could be characterized by patients' logistic and economic challenges. Aim of the present...
3.
Beghi E, Bosetti C, Ponzio M, Santucci C, Lepore V, Aguglia U, et al.
Neurol Sci
. 2022 Jun;
43(9):5459-5469.
PMID: 35672479
Background: Multiple sclerosis (MS) is characterized by phenotypical heterogeneity, partly resulting from demographic and environmental risk factors. Socio-economic factors and the characteristics of local MS facilities might also play a...
4.
Ferraro D, Iaffaldano P, Guerra T, Inglese M, Capobianco M, Brescia Morra V, et al.
J Neurol
. 2021 Jul;
269(3):1463-1469.
PMID: 34292396
Background: Fingolimod (FTY) induces sequestration of lymphocytes in secondary lymphoid organs and the average lymphocyte recovery following discontinuation takes 1-2 months. It has been hypothesized that the therapeutic effects of...
5.
Marvaso G, Corrao G, Oneta O, Pepa M, Zaffaroni M, Corso F, et al.
Clin Transl Oncol
. 2021 Mar;
23(8):1717-1726.
PMID: 33687659
Background And Purpose: Renal cell carcinoma (RCC) has traditionally been considered radioresistant with a limited role for conventional fractionation as a local approach. Nevertheless, since the appearance of stereotactic body...
6.
Dicuonzo S, Leonardi M, Raimondi S, Corrao G, Bagnardi V, Gerardi M, et al.
Clin Transl Oncol
. 2021 Feb;
23(7):1415-1428.
PMID: 33537865
Aims: To report toxicity of a hypofractionated scheme of whole-breast (WB) intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) to the tumor bed (TB) using Tomotherapy with Direct modality. Methods:...
7.
Baroncini D, Annovazzi P, Guaschino C, Minonzio G, Hametner S, Stadelmann C, et al.
Mult Scler Relat Disord
. 2020 Mar;
41:102061.
PMID: 32203930
No abstract available.
8.
Mallucci G, Annovazzi P, Miante S, Torri-Clerici V, Matta M, La Gioia S, et al.
J Neurol
. 2018 Jun;
265(8):1850-1859.
PMID: 29948245
Background: Dimethyl-fumarate (DMF) demonstrated efficacy and safety in relapsing-remitting multiple sclerosis (MS) in randomized clinical trials. Objectives: To track and evaluate post-market DMF profile in real-world setting. Materials And Methods:...
9.
Loraschi A, Bellantonio P, Bortolon F, Capra R, Cavalla P, Costantino G, et al.
Neurol Sci
. 2016 Feb;
37(4):613-22.
PMID: 26895323
Though recent progress in multiple sclerosis (MS) treatment is remarkable, numerous unmet needs remain to be addressed often inducing patients to look for complementary and alternative medicines (CAM), especially herbal...
10.
Ghezzi A, Zaffaroni M, Filippi M, Reganati P, Zibetti A
Eur J Neurol
. 2013 Nov;
2(2):139-41.
PMID: 24283615
Seventeen chronic progressive multiple sclerosis patients were treated with natural interferon-beta (IFN-β) for 2 years, thereafter they were followed up for 2 years. IFN-β was given 1 million IU/day i.m....